Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 30, 2024

BUY
$73.17 - $99.79 $9,585 - $13,072
131 New
131 $12,000
Q3 2022

Oct 26, 2022

SELL
$49.93 - $77.7 $155,531 - $242,035
-3,115 Reduced 43.54%
4,040 $266,000
Q1 2022

May 13, 2022

SELL
$54.1 - $110.08 $21,315 - $43,371
-394 Reduced 5.22%
7,155 $457,000
Q4 2021

Feb 14, 2022

SELL
$94.25 - $115.99 $27,144 - $33,405
-288 Reduced 3.67%
7,549 $808,000
Q2 2021

Jul 27, 2021

SELL
$82.78 - $101.0 $2,814 - $3,434
-34 Reduced 0.43%
7,837 $689,000
Q1 2021

May 11, 2021

BUY
$90.71 - $108.28 $283,468 - $338,375
3,125 Added 65.84%
7,871 $765,000
Q4 2020

Feb 09, 2021

SELL
$92.08 - $124.48 $138,488 - $187,217
-1,504 Reduced 24.06%
4,746 $532,000
Q3 2020

Oct 20, 2020

BUY
$66.45 - $92.7 $25,915 - $36,153
390 Added 6.66%
6,250 $579,000
Q2 2020

Jul 02, 2020

BUY
$57.09 - $79.27 $41,104 - $57,074
720 Added 14.01%
5,860 $457,000
Q1 2020

Apr 01, 2020

BUY
$48.11 - $82.22 $67,354 - $115,108
1,400 Added 37.43%
5,140 $300,000
Q4 2019

Feb 11, 2020

SELL
$66.73 - $82.59 $56,720 - $70,201
-850 Reduced 18.52%
3,740 $299,000
Q3 2019

Oct 09, 2019

BUY
$72.9 - $101.41 $137,052 - $190,650
1,880 Added 69.37%
4,590 $337,000
Q2 2019

Aug 14, 2019

BUY
$73.54 - $97.8 $57,361 - $76,284
780 Added 40.41%
2,710 $256,000
Q1 2019

May 08, 2019

SELL
$48.7 - $86.6 $3,409 - $6,062
-70 Reduced 3.5%
1,930 $154,000
Q4 2018

Feb 13, 2019

BUY
$45.57 - $74.26 $17,772 - $28,961
390 Added 24.22%
2,000 $107,000
Q3 2018

Nov 14, 2018

BUY
$58.91 - $78.32 $94,845 - $126,095
1,610 New
1,610 $126,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $7.66B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Nelson, Van Denburg & Campbell Wealth Management Group, LLC Portfolio

Follow Nelson, Van Denburg & Campbell Wealth Management Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nelson, Van Denburg & Campbell Wealth Management Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nelson, Van Denburg & Campbell Wealth Management Group, LLC with notifications on news.